GlaxoSmithKline: Respiration Disorders trials

The registry lists 22 Respiration Disorders studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 10Phase 2 4Phase 3 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix VaccineCompletedNCT03894969Phase 2Results posted
• A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the VaccineCompletedNCT03443427Phase 2Results posted
• A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.CompletedNCT03281876Phase 2Results posted
• A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in AdultsCompletedNCT03201211Phase 1Results posted
• Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia PacificCompletedNCT03151395Not applicableResults posted
• A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.CompletedNCT02547974Phase 1Results posted
• A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.CompletedNCT02075541Phase 2Results posted
• A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPDCompletedNCT01516437Not applicableResults posted
• Infectious Pathogens in Acute Respiratory Illness in Adults and ElderlyCompletedNCT01360398Not applicableResults posted
• Prophylactic Efficacy of Relenza Against Influenza A and BCompletedNCT01156701Results posted
• A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughActive, not recruitingNCT05600777Phase 3
• A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughCompletedNCT05599191Phase 3
• Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild AsthmaCompletedNCT05398198Phase 1
• Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under Fasting ConditionsCompletedNCT02658422Phase 1
• Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult SubjectsCompletedNCT02322671Phase 1
• A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy VolunteersCompletedNCT01818024Phase 1
• A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former SmokersCompletedNCT01678677Phase 1
• Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) VaccineCompletedNCT01657526Phase 1
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057CompletedNCT01587807Phase 1
• Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.CompletedNCT01476046Phase 1
• Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)CompletedNCT01395862
• Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)CompletedNCT01395849